Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report-Reference-Cited by-同舟云学术

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report

Published:2024-02-13 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Zhang Yao¹,Yang Jiayao¹,Shao Tianyu²,Chen Jialu³,Shu Qijin⁴,Shou Liumei⁴^ORCID

Affiliation:

1. The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China

2. Department of Oncology, Guang’ Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

3. Department of Oncology, Hangzhou Third People’s Hospital, Hangzhou, China

4. Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China

Funder

Projects of Department of Science and Technology of National Administration of Traditional Chinese Medicine and Administration of Traditional Chinese Medicine of Zhejiang Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2313281

Reference31 articles.

1. PD-L1 predicts chemotherapy resistance in large-cell neuroendocrine carcinoma

2. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

3. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study

4. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors

5. Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study